Increased Resistance of SARS-CoV-2 Omicron Variant to Neutralization by Vaccine-Elicited and Therapeutic Antibodies

Takuya Tada,Hao Zhou,Belinda M. Dcosta,Marie I. Samanovic,Vidya Chivukula,Ramin S. Herati,Stevan R. Hubbard,Mark J. Mulligan,Nathaniel R. Landau

DOI: https://doi.org/10.1016/j.ebiom.2022.103944

IF: 11.205

2022-01-01

EBioMedicine

Abstract:Background SARS-CoV-2 vaccines currently authorized for emergency use have been highly successful in prevent -ing infection and lessening disease severity. The vaccines maintain effectiveness against earlier SARS-CoV-2 Var-iants of Concern but the heavily mutated, highly transmissible Omicron variant presents an obstacle both to vaccine protection and monoclonal antibody therapies. Methods Pseudotyped lentiviruses were incubated with serum from vaccinated and boosted donors or therapeutic monoclonal antibody and then applied to target cells. After 2 days, luciferase activity was measured in a microplate luminometer. Resistance mutations of the Omicron spike were identified using point-mutated spike protein pseudo-types and mapped onto the three-dimensional spike protein structure. Findings Virus with the Omicron spike protein was 26-fold resistant to neutralization by recovered donor sera and 26-34-fold resistance to Pfizer BNT162b2 and Moderna vaccine-elicited antibodies following two immunizations. A booster immunization increased neutralizing titres against Omicron. Neutralizing titres against Omicron were increased in the sera with a history of prior SARS-CoV-2 infection. Analysis of the therapeutic monoclonal antibod-ies showed that the Regeneron and Eli Lilly monoclonal antibodies were ineffective against the Omicron pseudotype while Sotrovimab and Evusheld were partially effective. Interpretation The results highlight the benefit of a booster immunization to protect against the Omicron variant and demonstrate the challenge to monoclonal antibody therapy. The decrease in neutralizing titres against Omicron suggest that much of the vaccine efficacy may rely on T cells. Copyright (C) 2022 Published by Elsevier B.V.